Microbes and Memory Loss: A New Frontier in Alzheimer’s Research
Mira Jiang
Alzheimer’s disease, the most common form of dementia, is traditionally viewed as a disease of the brain—one defined by the progressive build-up of amyloid plaques, tau tangles, and the slow erosion of memory and cognition. For decades, research has centered on these hallmarks within the brain itself. But a growing body of evidence is challenging this brain-centric view, pointing instead to an unlikely accomplice in the development of Alzheimer’s—the gut.
The gut-brain axis—a bidirectional communication system between the gastrointestinal tract and the central nervous system—has become a central focus in understanding the roots of neurodegenerative disease. This axis is heavily influenced by the gut microbiome, a vast ecosystem of trillions of bacteria that produce neurotransmitters, modulate inflammation, and influence the integrity of the blood-brain barrier.
Multiple studies have revealed that people with Alzheimer’s have gut microbiomes that differ significantly from those of healthy individuals. On average, they show less microbial diversity, including a drop in beneficial bacteria that produce anti-inflammatory compounds like butyrate (Vogt et al., 2017). At the same time, some Alzheimer’s patients harbor higher levels of pro-inflammatory bacteria—the kind that produce toxic byproducts like lipopolysaccharides (LPS), which have been found in increased amounts in the blood and brains of Alzheimer’s patients (Zhao et al., 2017).
This imbalance, known as dysbiosis, may lead to increased gut permeability or “leaky gut.” When the gut lining becomes more porous, substances like LPS can escape into the bloodstream, triggering widespread inflammation. From there, the consequences ripple outward. Inflammation compromises the blood–brain barrier, the protective filter between the brain and the rest of the body. As the barrier weakens, inflammatory molecules and microbial fragments can invade the brain, activating immune cells and exacerbating Alzheimer’s pathology (Tran & Mohajeri, 2021).
The link between gut microbes and Alzheimer’s becomes even more compelling when looking at microglia—the brain’s resident immune cells. In a healthy brain, microglia clean up debris and keep neurons in check. When chronically activated by inflammation though, they can become destructive, releasing cytokines that damage brain cells and promote the build-up of amyloid plaques and tau tangles. In mouse models, removing the gut microbiome—either by raising animals in germ-free environments or through antibiotics—has been shown to reduce microglial activation and even decrease amyloid plaque formation (Harach et al., 2017). In contrast, reintroducing specific microbial metabolites like short-chain fatty acids can increase amyloid plaque deposition, suggesting that microbial signals may play a causal role in disease progression (Colombo et al., 2021).
If gut imbalance contributes to cognitive decline, could restoring a healthy microbiome help prevent or slow Alzheimer’s? Emerging research suggests it’s possible. In a randomized clinical trial, Alzheimer’s patients who consumed a daily probiotic supplement for 12 weeks experienced modest but significant improvements in memory and cognition, along with reductions in inflammation markers (Akbari et al., 2016). Other studies have tested Mediterranean-style or ketogenic diets, finding not only improved gut microbiome composition but also better performance on cognitive tests and improved levels of key Alzheimer’s biomarkers in cerebrospinal fluid (Nagpal et al., 2019; Kim et al., 2021). More radically, fecal microbiota transplants, where gut bacteria from healthy donors are transferred to recipients, have shown early promise in small observational studies. Some patients with dementia who received these transplants for unrelated infections showed improvements in memory and daily functioning post-transplant (Hazan, 2020).
Alzheimer’s remains a devastating, complex disease with no single cause and no definitive cure. But as our understanding of the gut-brain connection deepens, we may be entering a new chapter in dementia research where brain health is no longer considered in isolation. Once viewed solely through the lens of amyloid plaques and genetic risk, Alzheimer’s is now being reimagined as a multifactorial disorder—one shaped by systemic processes like inflammation, metabolism, and immunity. As research continues to explore the connection between digestive health and brain function, treating this disease may require an unconventional roadmap, one that goes beyond the brain and into the gut.
About the Author
Mira Jiang (‘26) is a junior at Harvard College concentrating in neuroscience.
References
The gut-brain axis—a bidirectional communication system between the gastrointestinal tract and the central nervous system—has become a central focus in understanding the roots of neurodegenerative disease. This axis is heavily influenced by the gut microbiome, a vast ecosystem of trillions of bacteria that produce neurotransmitters, modulate inflammation, and influence the integrity of the blood-brain barrier.
Multiple studies have revealed that people with Alzheimer’s have gut microbiomes that differ significantly from those of healthy individuals. On average, they show less microbial diversity, including a drop in beneficial bacteria that produce anti-inflammatory compounds like butyrate (Vogt et al., 2017). At the same time, some Alzheimer’s patients harbor higher levels of pro-inflammatory bacteria—the kind that produce toxic byproducts like lipopolysaccharides (LPS), which have been found in increased amounts in the blood and brains of Alzheimer’s patients (Zhao et al., 2017).
This imbalance, known as dysbiosis, may lead to increased gut permeability or “leaky gut.” When the gut lining becomes more porous, substances like LPS can escape into the bloodstream, triggering widespread inflammation. From there, the consequences ripple outward. Inflammation compromises the blood–brain barrier, the protective filter between the brain and the rest of the body. As the barrier weakens, inflammatory molecules and microbial fragments can invade the brain, activating immune cells and exacerbating Alzheimer’s pathology (Tran & Mohajeri, 2021).
The link between gut microbes and Alzheimer’s becomes even more compelling when looking at microglia—the brain’s resident immune cells. In a healthy brain, microglia clean up debris and keep neurons in check. When chronically activated by inflammation though, they can become destructive, releasing cytokines that damage brain cells and promote the build-up of amyloid plaques and tau tangles. In mouse models, removing the gut microbiome—either by raising animals in germ-free environments or through antibiotics—has been shown to reduce microglial activation and even decrease amyloid plaque formation (Harach et al., 2017). In contrast, reintroducing specific microbial metabolites like short-chain fatty acids can increase amyloid plaque deposition, suggesting that microbial signals may play a causal role in disease progression (Colombo et al., 2021).
If gut imbalance contributes to cognitive decline, could restoring a healthy microbiome help prevent or slow Alzheimer’s? Emerging research suggests it’s possible. In a randomized clinical trial, Alzheimer’s patients who consumed a daily probiotic supplement for 12 weeks experienced modest but significant improvements in memory and cognition, along with reductions in inflammation markers (Akbari et al., 2016). Other studies have tested Mediterranean-style or ketogenic diets, finding not only improved gut microbiome composition but also better performance on cognitive tests and improved levels of key Alzheimer’s biomarkers in cerebrospinal fluid (Nagpal et al., 2019; Kim et al., 2021). More radically, fecal microbiota transplants, where gut bacteria from healthy donors are transferred to recipients, have shown early promise in small observational studies. Some patients with dementia who received these transplants for unrelated infections showed improvements in memory and daily functioning post-transplant (Hazan, 2020).
Alzheimer’s remains a devastating, complex disease with no single cause and no definitive cure. But as our understanding of the gut-brain connection deepens, we may be entering a new chapter in dementia research where brain health is no longer considered in isolation. Once viewed solely through the lens of amyloid plaques and genetic risk, Alzheimer’s is now being reimagined as a multifactorial disorder—one shaped by systemic processes like inflammation, metabolism, and immunity. As research continues to explore the connection between digestive health and brain function, treating this disease may require an unconventional roadmap, one that goes beyond the brain and into the gut.
About the Author
Mira Jiang (‘26) is a junior at Harvard College concentrating in neuroscience.
References
- Akbari, E., Asemi, Z., Daneshvar Kakhaki, R., Bahmani, F., Kouchaki, E., Tamtaji, O. R., Hamidi, G. A., & Salami, M. (2016). Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial. Frontiers in aging neuroscience, 8, 256. https://doi.org/10.3389/fnagi.2016.00256
- Colombo, A. V., Sadler, R. K., Llovera, G., Singh, V., Roth, S., Heindl, S., Sebastian Monasor, L., Verhoeven, A., Peters, F., Parhizkar, S., Kamp, F., Gomez de Aguero, M., MacPherson, A. J., Winkler, E., Herms, J., Benakis, C., Dichgans, M., Steiner, H., Giera, M., Haass, C., … Liesz, A. (2021). Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition. eLife, 10, e59826. https://doi.org/10.7554/eLife.59826
- Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., & Bolmont, T. (2017). Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Scientific reports, 7, 41802. https://doi.org/10.1038/srep41802
- Hazan S. (2020). Rapid improvement in Alzheimer's disease symptoms following fecal microbiota transplantation: a case report. The Journal of international medical research, 48(6), 300060520925930. https://doi.org/10.1177/0300060520925930
- Kim, C. S., Cha, L., Sim, M., Jung, S., Chun, W. Y., Baik, H. W., & Shin, D. M. (2021). Probiotic Supplementation Improves Cognitive Function and Mood with Changes in Gut Microbiota in Community-Dwelling Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. The journals of gerontology. Series A, Biological sciences and medical sciences, 76(1), 32–40. https://doi.org/10.1093/gerona/glaa090
- Kowalski, K., & Mulak, A. (2019). Brain-Gut-Microbiota Axis in Alzheimer's Disease. Journal of neurogastroenterology and motility, 25(1), 48–60. https://doi.org/10.5056/jnm18087
- Nagpal, R., Neth, B. J., Wang, S., Craft, S., & Yadav, H. (2019). Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment. EBioMedicine, 47, 529–542. https://doi.org/10.1016/j.ebiom.2019.08.032
- Tran, S. M., & Mohajeri, M. H. (2021). The Role of Gut Bacterial Metabolites in Brain Development, Aging and Disease. Nutrients, 13(3), 732. https://doi.org/10.3390/nu13030732
- Vogt, N. M., Kerby, R. L., Dill-McFarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S. C., Carlsson, C. M., Asthana, S., Zetterberg, H., Blennow, K., Bendlin, B. B., & Rey, F. E. (2017). Gut microbiome alterations in Alzheimer's disease. Scientific reports, 7(1), 13537. https://doi.org/10.1038/s41598-017-13601-y
- Zhao, N., Liu, C. C., Qiao, W., & Bu, G. (2018). Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease. Biological psychiatry, 83(4), 347–357. https://doi.org/10.1016/j.biopsych.2017.03.00